MAIA Biotechnology, Inc. announced positive efficacy data for third-line treatment in its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) in advanced non-small cell lung cancer (NSCLC). THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. THIO's efficacy in non-small cell lung cancer ("NSCLC") is being evaluated in THIO-101, a Phase 2 go-to-market clinical trial nearing completion, which is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment.

MAIA plans to pursue the FDA's accelerated approval program for THIO. For example, all statements make regarding (i) the initiation, timing, cost, progress and results of preclinical and clinical studies and research and development programs, (ii) ability to develop, manufacture and commercialize the product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of the product candidates, (vi) the size and growth potential of the markets for the product candidates and ability to serve those markets, and (vii) expectations regarding the ability to obtain and maintain intellectual property protection for the product candidates, are forward looking. THIO's efficacy in Non-small cell lung cancer (NSCLC) is being evaluated in THIO, a Phase 2 go- to-market clinical trial nearing completion.

The Phase 2 go-to- market clinical trial nearing completion, which are expected to be the first completedclinical study of a telomere -targeting agent in the fieldof cancer drug discovery and treatment.MAIA plans to pursue the FDA' accelerated approval program for THIO". For example, all statements make approximately (i) the initiation, scheduling, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iii) the timing and likelihood of regulatory filings and approval, (iv) the timing or likelihood of Regulatory filings and approvals, (iv) the timing and degree of market acceptance of product candidates, (vi) The size and growth potential of the market acceptance of the product candidates and to serve those markets, and(vii) expectations regarding the capabilities regarding the ability to obtain and maintaining intellectual property protection for the product candidate. THIO's efficacy innon-small cell lung cancer (CNSCLC) is being evaluated In THIO-101, a phase 2 go-to-marketclinical trial nearing completion, which is expects to be the first completed clinical trial of a telomere- targeting agent in the field of drug discovery and treatment.

MAia plans to pursue the FDA's accelerate approval program for THIO.